Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

References

• SelmanMKingTEPardoAIdiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapyAnn Intern Med200113413615111177318
   PubMed Web of Science ®Google Scholar
• GrossTJHunninghakeGWIdiopathic pulmonary fibrosisN Engl J Med200134551752511519507
   PubMed Web of Science ®Google Scholar
• KingTEJrPardoASelmanMIdiopathic pulmonary fibrosisLancet201137898071949196121719092
   PubMed Web of Science ®Google Scholar
• CrosbyLMWatersCMEpithelial repair mechanisms in the lungAm J Physiol Lung Cell Mol Physiol2010298L71573120363851
   PubMed Web of Science ®Google Scholar
• ArmaniosMYChenJJCoganJDTelomerase mutations in families with idiopathic pulmonary fibrosisN Engl J Med20073561317132617392301
   PubMed Web of Science ®Google Scholar
• TsakiriKDCronkhiteJTKuanPJAdult-onset pulmonary fibrosis caused by mutations in telomeraseProc Natl Acad Sci U S A20071047552755717460043
   PubMed Web of Science ®Google Scholar
• MushirodaTWattanapokayakitSTakahashiAA genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosisJ Med Genet2008451065465618835860
   PubMed Web of Science ®Google Scholar
• FingerlinTEMurphyEZhangWGenome-wide association study identifies multiple susceptibility loci for pulmonary fibrosisNat Genet201345661362023583980
   PubMed Web of Science ®Google Scholar
• PeljtoALZhangYFingerlinTEAssociation between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosisJAMA2013309212232233923695349
   PubMed Web of Science ®Google Scholar
• TsujinoKTakedaYAraiTTetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrityAm J Respir Crit Care Med2012186217018022592804
   PubMed Web of Science ®Google Scholar
• LotaHKWellsAUThe evolving pharmacotherapy of pulmonary fibrosisExpert Opin Pharmacother2013141798923265249
   PubMed Web of Science ®Google Scholar
• RaghuGAnstromKJKingTEJrIdiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosisN Engl J Med20123661968197722607134
   PubMed Web of Science ®Google Scholar
• AzumaAPirfenidone treatment of idiopathic pulmonary fibrosisTher Adv Respir Dis20126210711422333982
   PubMed Web of Science ®Google Scholar
• MargolinSBinventorJohnHassigneeComposition for reparation and prevention of fibrotic lesions United States patent US 57166322101998
   Google Scholar
• MargolinSBLefkowitzSPirfenidone: a novel pharmacologic agent for prevention and resolution of lung fibrosisFASEB J19948A382
   Web of Science ®Google Scholar
• IyerSNWildJSSchiedtMJHydeDMMargolinSBGiriSNDietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamstersJ Lab Clin Med199512567797857539478
   PubMed Web of Science ®Google Scholar
• SchelegleESMansoorJKGiriSPirfenidone attenuates bleomycin-induced changes in pulmonary function in hamstersProc Soc Exp Biol Med199721633923979402144
   PubMed Web of Science ®Google Scholar
• Macías-BarragánJSandoval-RodríguezANavarro-PartidaJArmendáriz-BorundaJThe multifaceted role of pirfenidone and its novel targetsFibrogenesis Tissue Repair201031620809935
   PubMedGoogle Scholar
• SchaeferCJRuhrmundDWPanLSeiwertSDKossenKAntifibrotic activities of pirfenidone in animal modelsEur Respir Rev201120120859721632796
   PubMedGoogle Scholar
• SharmaKIxJHMathewAVPirfenidone for diabetic nephropathyJ Am Soc Nephrol20112261144115121511828
   PubMed Web of Science ®Google Scholar
• CainWCStuartRWLefkowitzDLStarnesJDMargolinSLefkowitzSSInhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidoneInt J Immunopharmacol199820126856959877280
   PubMed Web of Science ®Google Scholar
• OkuHNakazatoHHorikawaTTsurutaYSuzukiRPirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shockEur J Pharmacol20024461–316717612098599
   PubMed Web of Science ®Google Scholar
• NakazatoHOkuHYamaneSTsurutaYSuzukiRA novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational levelEur J Pharmacol20024461–317718512098600
   PubMed Web of Science ®Google Scholar
• OkuHShimizuTKawabataTAntifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosisEur J Pharmacol20085901–340040818598692
   PubMed Web of Science ®Google Scholar
• GurujeyalakshmiGHollingerMAGiriSNPirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational levelAm J Physiol1999276L3113189950894
   PubMed Web of Science ®Google Scholar
• FernandezIEEickelbergOThe impact of TGF-β on lung fibrosis: from targeting to biomarkersProc Am Thorac Soc20129311111622802283
   PubMedGoogle Scholar
• ArtlettCMInflammasomes in wound healing and fibrosisJ Pathol2013229215716723023641
   PubMed Web of Science ®Google Scholar
• WangYWuYChenJZhaoSLiHPirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formationCardiology2013126111123839341
   PubMed Web of Science ®Google Scholar
• RochePCzubrytMPPirfenidone and the inflammasome: Getting to the heart of cardiac remodelingCardiology20131261596123867498
   PubMed Web of Science ®Google Scholar
• MisraHPRabideauCPirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicalsMol Cell Biochem200020411912610718632
   PubMed Web of Science ®Google Scholar
• GagginiFLaleuBOrchardMDesign, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitorsBioorg Med Chem201119236989699922041175
   PubMed Web of Science ®Google Scholar
• HiranoAKanehiroAOnoKPirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challengeAm J Respir Cell Mol Biol20063536637716675785
   PubMed Web of Science ®Google Scholar
• VisnerGALiuFBizargityPPirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponsesTransplantation200988333033819667934
   PubMed Web of Science ®Google Scholar
• OkazakiAOhkuraNFujimuraMKatayamaNKasaharaKEffects of pirfenidone on increased cough reflex sensitivity in guinea pigsPulm Pharmacol Ther201326560360823817007
   PubMed Web of Science ®Google Scholar
• KakugawaTMukaeHHayashiTPirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosisEur Respir J2004241576515293605
   PubMed Web of Science ®Google Scholar
• HisatomiKMukaeHSakamotoNPirfenidone inhibits TGF-β1- induced over-expression of collagen type I and heat shock protein 47 in A549 cellsBMC Pulm Med2012122422694981
   PubMed Web of Science ®Google Scholar
• YangYYeYLinXWuKYuMInhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transition of human lens epithelial cells line SRA01/04PLoS One201382e5683723437252
   PubMed Web of Science ®Google Scholar
• RaghuGJohnsonWCLockhartDMagetoYTreatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II studyAm J Respir Crit Care Med19991591061106910194146
   PubMed Web of Science ®Google Scholar
• NagaiSHamadaKShigematsuMTaniyamaMYamauchiSIzumiTOpen-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosisIntern Med200241121118112312521199
   PubMed Web of Science ®Google Scholar
• AzumaANukiwaTTsuboiEDouble-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosisAm J Respir Crit Care Med200517191040104715665326
   PubMed Web of Science ®Google Scholar
• TaniguchiHEbinaMKondohYPirfenidone in idiopathic pulmonary fibrosis: a Phase III clinical trial in JapanEur Respir J201035482182919996196
   PubMed Web of Science ®Google Scholar
• NoblePWAlberaCBradfordWZPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsLancet20113771760176921571362
   PubMed Web of Science ®Google Scholar
• BajwahSRossJRPeacockJLInterventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literatureThorax201368986787923204065
   PubMed Web of Science ®Google Scholar
• SpagnoloPDel GiovaneCLuppiFNon-steroid agents for idiopathic pulmonary fibrosisCochrane Database Syst Rev201089CD00313420824834
   PubMed Web of Science ®Google Scholar
• CollardHRKingTEJrBartelsonBBVourlekisJSSchwarzMIBrownKKChanges in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2003168553854212773325
   PubMed Web of Science ®Google Scholar
• ZappalaCJLatsiPINicholsonAGMarginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosisEur Respir J20103583083519840957
   PubMed Web of Science ®Google Scholar
• RaghuGCollardHRAnstromKJIdiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trialsAm J Respir Crit Care Med2012185101044104822505745
   PubMed Web of Science ®Google Scholar
• du BoisRMNathanSDRicheldiLSchwarzMINoblePWIdiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trialsAm J Respir Crit Care Med2012186871271522798316
   PubMed Web of Science ®Google Scholar
• WellsAUBehrJCostabelUCottinVPolettiVRicheldiLfor European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the goodThorax2012671193894023047830
   PubMed Web of Science ®Google Scholar
• KingTEAlberaCBradfordWZAll-cause mortality (ACM) rate in patients with idiopathic pulmonary fibrosis (IPF): implications for the design and execution of mortality trialsATS2013A2356
   Google Scholar
• VancheriCdu BoisRMA progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancerEur Respir J201341226226922903965
   PubMed Web of Science ®Google Scholar
• AzumaATaguchiYOguraTExploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatmentRespir Res20111214322035508
   PubMed Web of Science ®Google Scholar
• TaniguchiHKondohYEbinaMThe clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trialRespir Res2011129321756364
   PubMed Web of Science ®Google Scholar
• CottinVCordierJFVelcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis?Eur Respir J201240351952122941541
   PubMed Web of Science ®Google Scholar
• OkudaRHagiwaraEBabaTKitamuraHKatoTOguraTSafety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practiceRespir Med201310791431143723849626
   PubMed Web of Science ®Google Scholar
• Shionogi & Co, LtdImmunosuppressive effect of pirfenidoneInternal Data Reference 200801771Shionogi & Co, Ltd2008 Japanese
   Google Scholar
• IwasawaTOguraTSakaiFCT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosisEur J Radiol2014831323822465123
   PubMed Web of Science ®Google Scholar
• ItoMNiimiYNakamuraAPost-marketing surveillance of pirfenidone for idiopathic pulmonary fibrosis in Japan: Interim analysis of 973 patientsERS Annual CongressSeptember 1–5, 2012Vienna, AustriaP3158
   Google Scholar
• RaghuGCollardHREganJJAn official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and managementAm J Respir Crit Care Med2011183678882421471066
   PubMed Web of Science ®Google Scholar
• BehrJEvidence-based treatment strategies in idiopathic pulmonary fibrosisEur Respir Rev20132212816316823728871
   PubMedGoogle Scholar
• XaubetAAncocheaJBolloEGuidelines for the diagnosis and treatment of idiopathic pulmonary fibrosisArch Bronconeumol201349834335323742884
   PubMed Web of Science ®Google Scholar
• HommaSAzumaATaniguchiHEfficacy of inhaled N- acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosisRespirology201217346747722257422
   PubMed Web of Science ®Google Scholar
• RothGJHeckelAColbatzkyFDesign, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)J Med Chem200952144466448019522465
   PubMed Web of Science ®Google Scholar
• RicheldiLCostabelUSelmanMEfficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosisN Engl J Med2011365121079108721992121
   PubMed Web of Science ®Google Scholar